Tonix Pharmaceuticals (TNXP) Set to Release Quarterly Earnings on Monday

Key Points

• Tonix Pharmaceuticals is expected to report Q3 2026 results before the market opens on November 9. Analysts anticipate a loss of $2.3885 per share and revenue of $16.32 million.
• In the previous quarter, Tonix reported a loss of $2.44 per share, beating estimates, while revenue of $13.54 million exceeded the $7.72 million consensus forecast. Analysts expect full-year and next-year losses of $9.90 and $6.62 per share, respectively.
• TNXP shares opened at $5.10, near their 12-month low of $4.96 and well below their 50-day and 200-day moving averages. Analyst opinion remains mixed, but the stock carries an overall “Buy” rating and a $22.33 average price target.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Tonix Pharmaceuticals to announce earnings of ($2.3885) per share and revenue of $16.32 million for the quarter. Investors can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($2.64) by $0.20. Tonix Pharmaceuticals had a negative return on equity of 68.99% and a negative net margin of 548.64%. The firm had revenue of $13.54 million during the quarter, compared to the consensus estimate of $7.72 million. On average, analysts expect Tonix Pharmaceuticals to post ($9.90) EPS for the current fiscal year and ($6.62) EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock opened at $5.10 on Monday. The firm has a market capitalization of $87.47 million, a price-to-earnings ratio of -0.39 and a beta of 1.90. The business's 50-day moving average price is $9.53 and its 200-day moving average price is $12.50. Tonix Pharmaceuticals has a 12 month low of $4.96 and a 12 month high of $20.56.

Wall Street Analyst Weigh In

TNXP has been the subject of a number of research reports. Raymond James Financial reiterated a "strong-buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday, October 20th. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, October 4th. Weiss Ratings restated a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. Finally, Canaccord Genuity Group started coverage on shares of Tonix Pharmaceuticals in a research note on Monday, October 26th. They set a "buy" rating and a $18.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $22.33.

Insider Activity

In related news, CEO Seth Lederman acquired 2,000 shares of the stock in a transaction dated Thursday, August 27th. The stock was bought at an average cost of $13.79 per share, for a total transaction of $27,580.00. Following the completion of the transaction, the chief executive officer directly owned 11,005 shares of the company's stock, valued at $151,758.95. The trade was a 22.21% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.00% of the stock is owned by company insiders.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving the central nervous system, immunology and infectious diseases. The company's research programs are designed to address disorders with significant unmet medical needs, including chronic pain, neuropsychiatric conditions and infectious diseases.

Tonix's pipeline has included TNX-102 SL, an investigational sublingual formulation of cyclobenzaprine being studied for fibromyalgia and other pain-related conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.